Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Enphase Energy Inc (ENPH) Price & Performance

AbbVie IncTrade
Enphase Energy IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Enphase Energy Inc — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Enphase Energy Inc trades at $42.32 (market cap $5.41B). The key difference: AbbVie Inc is far larger — about 81× Enphase Energy Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.

ABBVENPH
Market Cap
$438.19B$5.41B
Sector
HealthTechnology
52-Week High
$263.58$72.33
52-Week Low
$197.38$26.12
Enterprise Value
$502.45B$5.05B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Enphase Energy Inc

Enphase Energy (ENPH) trades at $41.87, up 5.55% with bullish technical signals and mixed quarterly earnings. The company reported Q2 2026 EPS of $0.46, missing expectations, while revenue declined 19.6% year-over-year. Recent product expansions in battery systems and U.S. manufacturing commitments provide growth catalysts, though residential solar demand remains volatile. Valuation metrics show a P/E of 41.46 and P/S of 4.2, reflecting premium pricing amid earnings normalization.

Outlook remains cautiously optimistic with analyst consensus price target of $45.37 offering 8% upside potential. Key opportunities include European storage growth and AI data center initiatives, while risks center on U.S. demand weakness and competitive pressures. The stock faces near-term resistance at $43-$45 levels with institutional ownership showing mixed positioning through recent filings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH